Don't Overreact to Dimon's Health Scare

 | Jul 02, 2014 | 11:24 AM EDT
  • Comment
  • Print Print
  • Print
Stock quotes in this article:








Jamie Dimon is a revered banker, mostly because JPMorgan Chase (JPM) made a lot of right moves in the last few years, chiefly building up a fortress balance sheet that shielded the company from the big losses that so many other banks have taken. That's why the sad news that he has throat cancer is causing the stock of this Action Alerts PLUS name to get hit today.

Should the stock be bought into the weakness?

First, you have to understand that when a company issues a release saying a CEO has cancer but it is curable cancer, and curable in a relatively short period, as is the case here, it is not a reason for selling.

That's because no executive wants to make a positive prognosis about such a horrible disease unless the doctors have given a huge amount of assurance that things will turn out well in the end. The stakes are too high, even for banks, which have a very tarnished reputation when it comes to veracity.

Second, and more important for stock-pickers, there have been three times that stand out when a noteworthy CEO has had to be treated for curable forms of cancer: the 1995 admission from Intel's (INTC) then-CEO, Andy Grove, the 2010 statement from Bob Benmosche, CEO of American International Group (AIG) and the 2012 announcement from Warren Buffett at Berkshire Hathaway (BRK.B).

All three situations proved to be buying opportunities. Intel, which was admittedly in the midst of one of the great '86 microprocessing cycles, doubled in the year after Grove got sick and then returned. Within a month, AIG and Berkshire Hathaway were both higher after the tough news each company released. The companies were true to their word, and all three came back in short order to lead their companies to further success.

Now not to be too grisly, but just playing it ultra-safe, JPMorgan does have a strong bench of executives underneath Dimon, including Gordon Smith, the excellent head of the highly successful consumer bank, and, perhaps, ultimately, Matt Zames, the 43-year-old chief operating officer, although he's a little young to be thought of in in the successor role right now.

No bank runs itself. JPMorgan has had a fairly sterling reputation among banks, but it hasn't all been roses under Dimon, including the "London whale" incident that led to a multi-billion charge and the gigantic $13 billion hit to earnings that Dimon agreed to pay the government for past transgressions. The last quarter itself was nothing to write home about either -- it was one of the weaker in the group.

All that said, this is a quality franchise with a stock that has gotten very cheap compared with the overall market. I think it is, in the end, a proxy, not so much for Dimon's management but for the U.S. and world economy, which I think is improving. That means, to me, that it is a buy on any material weakness on this difficult news.

Tough to say "buying opportunity on curable cancer," but if history be the judge, it should be. 

Would you like to test drive all of TheStreet's premium products for free? Sign up for our all-access pass for July at absolutely no cost to you and read Action Alerts PLUS picks from me and Stephanie Link, Doug Kass' Daily Diary on Real Money Pro, Stocks Under $10 picks from David Peltier and much more. Learn more here.

Columnist Conversations

Now that AAPL has violated the shorter term support, these are the two areas I have to consider for new buy en...
The symmetry is holding up in MCD.  Target 1 is 163.34 if we continue to hold above here!  ...
As far as TSLA is concerned, I still have a higher target above the market at the 409 area.  I stated in ...
The TLT setup discussed in my last commentary is a bust. Key support was violated and it violated the recent l...



News Breaks

Powered by


Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.